REG - Renalytix PLC - Rule 2.9 Announcement

RenalytixAnnouncement

16/04/2024 13:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240416:nRSP8404Ka&default-theme=true

RNS Number : 8404K  Renalytix PLC  16 April 2024

 

 

Renalytix plc

("Renalytix" or the "Company")

 

Rule 2.9 Announcement

 

LONDON and SALT LAKE CITY, 16 April 2024 - Renalytix plc
(https://urldefense.com/v3/__https:/renalytix.com/__;!!OPvj_Mo!5NjuO3d4ZKKNy3CAS5zrlIoL4v77Z1jUxLn_SzH6VpmCLKJ4uV-vaEXz1QL81Z_81bVMj7e5kEYRXU0_CqbZ$)
 (NASDAQ: RNLX) (LSE: RENX), in accordance with Rule 2.9 of the City Code on
Takeovers and Mergers ("Takeover Code") and further to the announcement on 15
April 2024
(https://investors.renalytix.com/news-releases/news-release-details/completion-financing-and-total-voting-rights)
, confirms that its issued share capital consists of 126,219,016 ordinary
shares of £0.0025 each in the capital of the Company (the "Ordinary Shares")
following the issuance of the Initial Tranche Shares of 2,666,667 Ordinary
Shares this morning.

 

The Company also has a sponsored Level III ADR programme. The ADSs are traded
on the Nasdaq Global Market and Citibank N.A. acts as the depositary for the
programme. Each ADS represents two Ordinary Shares.  No shares are held in
treasury. The total number of voting rights in the Company is therefore
126,219,016.

 

The International Securities Identification Number for the Ordinary Shares is
GB00BYWL4Y04.

 

The International Securities Identification Number for the ADSs is
US75973T1016.

 

Capitalised terms used but not defined in this announcement have the meanings
given to them in the announcement dated 15 April 2024, unless the context
provides otherwise.

 

For further information, please contact:

 

 Renalytix plc                                                  www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                                          Via Walbrook PR

 Stifel (Nominated Adviser, Joint Broker)                       Tel: 020 7710 7600
 Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

 Investec Bank plc (Joint Broker)                               Tel: 020 7597 4000
 Gary Clarence / Shalin Bhamra

 Walbrook PR Limited                                            Tel: 020 7933 8780 or renalytix@walbrookpr.com

                                                              (mailto:renalytix@walbrookpr.com)
 Paul McManus / Alice Woodings /

                                                              Mob: 07980 541 893 / 07407 804 654 /
 Charlotte Edgar

                                                                07884 664 686

 CapComm Partners
 Peter DeNardo                                                  Tel: 415-389-6400 or investors@renalytix.com (http://investors@renalytix.com)

 

 

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory
services company that is the global founder and leader in the new field of
bioprognosis™ for kidney health. The leadership team, with a combined 200+
years of healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment for rapid
progressive decline in kidney function in adult patients with T2D and early
CKD (stages 1-3). We believe that by understanding how disease will progress,
patients and providers can take action early to improve outcomes and reduce
overall health system costs. For more information, visit www.renalytix.com.

 

Disclosure requirements of the Takeover Code

Under Rule 8.3(a) of the Takeover Code, any person who is interested in one
per cent. or more of any class of relevant securities of an offeree company or
of any securities exchange offeror (being any offeror other than an offeror in
respect of which it has been announced that its offer is, or is likely to be,
solely in cash) must make an Opening Position Disclosure following the
commencement of the offer period and, if later, following the announcement in
which any securities exchange offeror is first identified.

 

An Opening Position Disclosure must contain details of the person's interests
and short positions in, and rights to subscribe for, any relevant securities
of each of (i) the offeree company and (ii) any securities exchange
offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a)
applies must be made by no later than 3.30 p.m. (London time) on the
10(th) business day following the commencement of the offer period and, if
appropriate, by no later than 3.30 p.m. (London time) on the
10(th) business day following the announcement in which any securities
exchange offeror is first identified. Relevant persons who deal in the
relevant securities of the offeree company or of a securities exchange offeror
prior to the deadline for making an Opening Position Disclosure must instead
make a Dealing Disclosure.

 

Under Rule 8.3(b) of the Takeover Code, any person who is, or becomes,
interested in one per cent. or more of any class of relevant securities of the
offeree company or of any securities exchange offeror must make a Dealing
Disclosure if the person deals in any relevant securities of the offeree
company or of any securities exchange offeror. A Dealing Disclosure must
contain details of the dealing concerned and of the person's interests and
short positions in, and rights to subscribe for, any relevant securities of
each of (i) the offeree company and (ii) any securities exchange offeror, save
to the extent that these details have previously been disclosed under Rule 8.
A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by
no later than 3.30 p.m. (London time) on the business day following the
date of the relevant dealing.

 

If two or more persons act together pursuant to an agreement or understanding,
whether formal or informal, to acquire or control an interest in relevant
securities of an offeree company or a securities exchange offeror, they will
be deemed to be a single person for the purpose of Rule 8.3.

 

Opening Position Disclosures must also be made by the offeree company and by
any offeror and Dealing Disclosures must also be made by the offeree company,
by any offeror and by any persons acting in concert with any of them (see
Rules 8.1, 8.2 and 8.4).

 

Details of the offeree and offeror companies in respect of whose relevant
securities Opening Position Disclosures and Dealing Disclosures must be made
can be found in the Disclosure Table on the Panel's website
at www.thetakeoverpanel.org.uk (http://www.thetakeoverpanel.org.uk/) ,
including details of the number of relevant securities in issue, when the
offer period commenced and when any offeror was first identified. You should
contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are
in any doubt as to whether you are required to make an Opening Position
Disclosure or a Dealing Disclosure.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RTTFLFIFSDIRLIS